P/E ratio for Galapagos NV (GLPG)
P/E ratio as of April 2024 (TTM): -11.0
According to Galapagos NV's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.9637. At the end of 2022 the company had a P/E ratio of -12.4.
P/E ratio history for Galapagos NV from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -12.4 | -58.07% |
| 2021 | -29.5 | 61.08% |
| 2020 | -18.3 | -121.64% |
| 2019 | 84.7 | -165.49% |
| 2018 | -129 | 271.22% |
| 2017 | -34.8 | -168.62% |
| 2016 | 50.7 | -395.82% |
| 2015 | -17.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -194.83% | 🇺🇸 USA |
 Abbott Laboratories ABT | 36.1 | -429.49% | 🇺🇸 USA |
 AbbVie ABBV | 43.7 | -499.00% | 🇺🇸 USA |
 Sanofi SNY | 15.3 | -239.39% | 🇫🇷 France |
 Merck MRK | 72.0 | -756.46% | 🇺🇸 USA |
 AstraZeneca AZN | 37.7 | -443.86% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 11.7 | -206.94% | 🇬🇧 UK |
 Fortress Biotech
FBIO | -0.1613 | -98.53% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -6.75 | -38.46% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.